Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
Abstract A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira $ Pak^{™} $) and those of the EU ($ Viekirax^{®} $ and $ Exviera^{®} $). In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virological response 12 weeks post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection. The regimen was generally well tolerated, with nausea, insomnia, asthenia, pruritus, other skin reactions and fatigue being among the most common tolerability issues. Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use ± ribavirin in a broad range of adults chronically infected with HCV genotype 1..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Drugs - 75(2015), 9 vom: Juni, Seite 1027-1038 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deeks, Emma D. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Ritonavir |
|---|
| Anmerkungen: |
© Springer International Publishing Switzerland 2015 |
|---|
| doi: |
10.1007/s40265-015-0412-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2037779194 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2037779194 | ||
| 003 | DE-627 | ||
| 005 | 20230516070409.0 | ||
| 007 | tu | ||
| 008 | 200819s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40265-015-0412-z |2 doi | |
| 035 | |a (DE-627)OLC2037779194 | ||
| 035 | |a (DE-He213)s40265-015-0412-z-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Deeks, Emma D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer International Publishing Switzerland 2015 | ||
| 520 | |a Abstract A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira $ Pak^{™} $) and those of the EU ($ Viekirax^{®} $ and $ Exviera^{®} $). In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virological response 12 weeks post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection. The regimen was generally well tolerated, with nausea, insomnia, asthenia, pruritus, other skin reactions and fatigue being among the most common tolerability issues. Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use ± ribavirin in a broad range of adults chronically infected with HCV genotype 1. | ||
| 650 | 4 | |a Sustained Virological Response | |
| 650 | 4 | |a Ritonavir | |
| 650 | 4 | |a Telaprevir | |
| 650 | 4 | |a Sofosbuvir | |
| 650 | 4 | |a SVR12 Rate | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d Springer International Publishing, 1971 |g 75(2015), 9 vom: Juni, Seite 1027-1038 |w (DE-627)129290211 |w (DE-600)120316-2 |w (DE-576)014471566 |x 0012-6667 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2015 |g number:9 |g month:06 |g pages:1027-1038 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s40265-015-0412-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_4012 | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2015 |e 9 |c 06 |h 1027-1038 | ||